Tag PBM

Wearable Photo-Bio-Modulation Light Therapy Device

One of the very effective and creative methods for Photo-bio-modulation use has been discovered by Advanced Materials Technologies. This method includes a wearable patch directly applied in-vitro, on the skin. Clickhere to read more…

Wearable Photo-Bio-Modulation Device

With the precedent of a flexible infrared‐wavelength organic light‐emitting diode (OLED), a now wearable photo-bio-modulation patch for wound healing is shown by Kyoung‐Chan Park, Kyung Cheol Choi, and their co‐workers in the above link. This wearable, material device promotes in vitrowound and joint healing. Some of it’s important characteristics is that it is reliable during operation, flexible, and operates at a low‐temperature, so that it can be used in any location and time, attached to the human body. It has an operational time of more than 300hours!

Wearable Photo-Bio-Modulation Light Therapy Device

Specifications of the device

‘Photo-bio-modulation (PBM) is a safe and noninvasive method that can provide various clinical effects. However, conventional PBM devices using point light sources, such as light‐emitting diodes and lasers have various disadvantages. These, such as low flexibility, relatively heavy weight, and nonuniform effects. We are now able to present a novel wearable PBM patch using a flexible red‐wavelength organic light‐emitting diode (OLED) surface light source, which can be attached to the human body as a personalised PBM platform. The palm‐sized wearable PBM patch can be very light (0.82 g) and thin (676 µm). It also has a reasonable operation life (>300 h), flexibility (20 mm bending radius), and low‐temperature operation (<40 °C), and it can provide wide and safe application irrespective of location and time. Fibroblasts, a major type of dermal cells, play a key role in the wound healing process. The results show that OLEDs may have excellent in vitro wound healing effects because they effectively stimulate fibroblast proliferation (over 58% of control) and enhance fibroblast migration (over 46% of control) under various conditions. For maximum effect, peak wavelength control is necessary to optimise cell proliferation and enhance in vitro wound healing effects.’

read more

Shining-light-on-the-head-pbm.jpg

Migraine and Headaches: PBM Showing Positive Results

Even more articles are being released from various patients and companies using this ‘state of the art’ technology of Photo-bio-moduation. Headache and migraine sufferers, who are tired of popping the pain pills, can finally have sigh of relief knowing that their discomfort can be alleviated with a modernised treatment. This specific treatment is known as Intranasal Photo-bio-modulation Therapy.

The Sphenopalatine Ganglion

A ganglion is a group of nerve axons. Nerves, as you may already know, ‘are like wires that connect the brain to the rest of the body in both directions. The sphenopalatine ganglion has several connections to the areas believed to have a causative factor in migraines.’ The cause of these sever headaches and migraines still, somehow, are unknown. 

The sphenopalatine ganglion has connections to three areas that are all believed to be related to headaches. Those areas are meeting points of the brain so this is the area which could be the source of headaches.

Shining Light on the Head: Photo-bio-modulation, treatment for migraine headaches Photo supplied by Science Direct

Shining Light on the Head: Photo-bio-modulation, treatment for migraine headaches
Photo supplied by Science Direct

SCIENCEY INFORMATION CONCERNING THE NERVES 

The superior cervical sympathetic ganglion, trigeminal nerve via connections with the maxillary nerve, and the suboccipital nerves at the base of the skull. They are all connected to the sphenopalatine ganglion which is the closest nerve to the outside of the body.

PBM

Intranasal photo-bio-modulation (administered through the nostrils) pumps light energy into the nerve by firing up ATP production. Adenosine triphosphate(ATP) is a complex organic chemical often called the “molecular unit of currency” of intracellular energy transfer. Simply think of the process of photo-bio-modulation as jumping the nerve batteries. The sphenopalatine ganglion has been the site of nasal opioid delivery for treatment of headaches. In some experiments, cocaine was used.

DISCLAIMER: We are not recommending the use of cocaine to treat migraines or headaches.

Photo-bio-modulation treatment, and the use of Low Level Light Therapy (LLLT)  shows great promise in the treatment of migraines and headaches. There will be more reports on this in the future. Watch this space!

To view the original article written by Darien of Core Health, click this link.

 

eyekandi life tech photobiomodulation LLLT

read more

LT-300-LED-1.jpg

LumiThera and LightSite I Making Waves

LIGHTSITE I

LumiThera Inc is a medical device company currently focused on developing a non-invasive Photobiomodulation therapy for ocular (eye) disorders and disease. Their pilot product LightSite I provided great results after their first clinical trial for the ‘treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System’. 

The results from the clinical trial was presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) annual conference by members of the LumiThera investigation team. The team consisted of: Marion Munk, MD, PhD, Department of Ophthalmology/Bern Photographic Reading Center and Managing Director, Bern Photographic Reading Center, University Hospital Bern. 

“LumiThera PBM treatment demonstrated reductions in central drusen volume over the course of the one-year study versus the sham treatment with statistical significance at one year, (p = 0.05).  Drusen is the hallmark pathology of dry AMD and is an important proinflammatory mediator and marker for disease progression,” says Dr. Munk.

“Results from the LIGHTSITE I study following treatment with a multi-wavelength PBM treatment demonstrated clinical improvements in vision outcome measures providing a strong foundation for initial therapy as well as the need for follow-up maintenance therapy,” stated Samuel Markowitz, M.D., Co-Principal Investigator, Department of Ophthalmology and Vision Sciences, University of Toronto.  “The PBM therapy was most beneficial in dry AMD patients immediately following the completion of the treatment sessions. Contrast sensitivity or detailed vision was significantly improved throughout the year. Retreatments at a 6 month interval were performed to maintain clinical benefits.”

LumiThera Light Site  LT-300 LED ophthalmologic instrument station provides a multi-wavelength approach to treating ocular disease.

LumiThera Light Site
LT-300 LED ophthalmologic instrument station provides a multi-wavelength approach to treating ocular disease.

“We are excited by the completion of the LIGHTSITE I trial and seeing the benefits in both clinical outcomes and drusen pathology,” stated Clark Tedford, Ph.D., LumiThera President and CEO. “The LT-300 Light Delivery System performance was excellent throughout the clinical trial and patients provided positive feedback from their PBM treatment experience over the course of a year. This foundational data will accelerate our learning to develop options to treat complicated degenerative eye disease, where patient options are limited. The results demonstrate that the therapy is both a safe and effective treatment for early stage dry AMD patients. The current trial results will be used to refine the upcoming multi-center clinical trials expected to start initially in Europe.”

“LumiThera’s LIGHTSITE I data is the first prospective, sham controlled, double-masked, pilot clinical dry AMD study with PBM,” says Dr. Robert Devenyi, Co-Principal Investigator, Ophthalmologist-in-Chief and Director of Retinal Services, UHN, University of Toronto. “The results show PBM using the LT-300 device can improve Visual Acuity and Contrast Sensitivity as vision endpoints for dry AMD patients to counteract the degradation in vision that this disabling disease brings.”

The pilot study consisted of 30 people and was partially funded by a grant from a Small Business Innovation Research fund, awarded to LumiThera from the National Institute of Health and the National Eye Institute.  The clinical trial tested each person’s vision and examined disease pathology in the eye, following PBM treatments for up to one year.

Visit the Company’s website at www.lumithera.com.

About LumiThera Inc.

LumiThera is a clinical-stage medical device company focused on treating people affected by ocular disorders and diseases including dry age-related macular degeneration, a leading cause of blindness in adults over 65. The Company is a leader in the use of Photobiomodulation for treatment of acute and chronic ocular diseases and disorders. The Company is developing the office-based LT-300 Light Delivery System to be used by ophthalmologists and other eye specialists as non-invasive medical treatments.

Important to note: The LT-300 is not yet approved for use by the Food & Drug Administration in the USA. The device has also not yet been granted a CE Mark by a Notified Body for commercial use outside of the USA.

The LT-300 LED ophthalmologic instrument station is designed to provide a multi-wavelength approach to treating ocular disease.

Working research and clinical units are being built to support ongoing research and development activities.

Lumithera logo

read more

red-light-therapy-Dave-asprey.png

Red Light Therapy Health Benefits and How to Get It

Still wondering about the Red Light Therapy phenomenon?

KEEP READING…

As seen on the Bulletproof Blog, Red light therapy, also known as photo-bio-modulation (PBM), has been around for around 40 years – ever since the invention of lasers.

“Red light therapy uses certain wavelengths of light to restore, repair, and protect tissue that is either injured, degenerating, or at risk of dying. While varying wavelengths affect the body differently, as far as healing with red light is concerned, the most effective wavelengths range from 630-670 and 810-880.”

But this is how it really works…

The PBM wavelengths affect bodily cells on a biochemical level by increasing mitochondrial function. This is the ability to produce energy in the cells. The more that the cells can produce energy, the better the body can function. When red light wavelengths are used on the skin’s surface, they penetrate 8-10 millimetres deep into the skin. So depending upon where the red light is used (head or knee, for instance), all of the surrounding skin layers, blood vessels, lymph pathways, nerves, and even hair follicles are affected.

Mr Dave Asprey of Bulletproof Radio Health Benefits of Red Light Therapy and How to Get It

Mr Dave Asprey of Bulletproof Radio
Health Benefits of Red Light Therapy and How to Get It

The Benefits of Red Light Therapy (PBM)

Red light therapy works from the inside-out to enhance and increase mitochondrial function in cells. Therefore this, leads to several skin benefits. Red light reduces skin inflammation, smooths skin tone, repairs sun damage, fades scars and stretch marks, and even builds collagen in the skin which in turn reduces wrinkles. It also heals wounds and can prevent recurring cold sores or herpes simplex (some of us were burdened). PBM works on the lymphatic system to improve your body’s detoxification abilities by increasing blood flow. It may even stimulate hair growth in your hair follicles (check it out ladies!).

Still interested?

See the original post on the Bulletproof Blog and see the informative video clip they posted!

read more